Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Chemotherapeutic drugs are cytotoxic by induction of apoptosis in drug-sensitive cells. We investigated the mechanism of bleomycin-induced cytotoxicity in hepatoma cells. At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2). Bleomycin did not increase CD95 in hepatoma cells with mutated p53 (Huh7) or in hepatoma cells which were p53-/- (Hep3B). In addition, sensitivity towards CD95-mediated apoptosis was also increased in wt p53 positive HepG2 cells. Microinjection of wt p53 cDNA into HepG2 cells had the same effect. In contrast, bleomycin did not enhance susceptibility towards CD95-mediated apoptosis in Huh7 and in Hep3B cells. Furthermore, bleomycin treatment of HepG2 cells increased CD95 ligand (CD95L) mRNA expression. Most notably, bleomycin-induced apoptosis in HepG2 cells was almost completely inhibited by antibodies which interfere with CD95 receptor/ligand interaction. These data suggest that apoptosis induced by bleomycin is mediated, at least in part, by p53-dependent stimulation of the CD95 receptor/ligand system. The same applies to other anti-cancer drugs such as cisplatin and methotrexate. These data may have major consequences for drug treatment of cancer and the explanation of drug sensitivity and resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“To examine whether synergy (39, 40) between APO-1 stimulation and concurrent bleomycin treatment is observed, a balanced two-way ANOVA (model with fixed effects) was performed.”
MethodNicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., & Riccardi, C. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90198-o · Cited by 4,579
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 4,252
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 1×
“On the other hand, bcl-2 and its antagonist bax have been shown to be regulated by p53 (68, 69).”
BackgroundKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81266-0 · Cited by 3,046 · cited 1×
“The death domain of the receptor binds to the death domain of the adapter molecule FADD, which binds and activates FLICE to generate the most apical enzymatic component of a death cascade composed of other ICE/CED-3 family members (61).”
BackgroundSelf-citationp53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Cited by
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
“To t his end, treatment with anticancer drugs triggered an increase in CD95L expression, which stimulated the receptor pathway in an autocrine or paracrine manner by binding to its receptor CD95 (Friesen et al., 1996; Fulda et al., 1997, 1998a; Houghton et al., 1997; Muller et al., 1997).”
BackgroundMethodDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Self-citationA Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
Induction of Apoptosis by Cancer Chemotherapy
Kaufmann, S. H., & Earnshaw, W. C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4838 · Cited by 1,266
Reed, J. C. (1998) · Oncogene · doi:10.1038/sj.onc.1202591 · Cited by 1,049
T cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
FADD: Essential for Embryo Development and Signaling from Some, But Not All, Inducers of Apoptosis
Yeh, W.-C., Pompa, J. L. D. L., McCurrach, M. E., Shu, H.-B., Elia, A. J., Shahinian, A., Ng, M., Wakeham, A., Khoo, W., Mitchell, K., et al. (1998) · Science · doi:10.1126/science.279.5358.1954 · Cited by 893
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
“The anticancer drugs 5-fluorouracil, methotrexate, mitomycin, cisplatin, mitoxantrone, doxorubicin, etoposide, cyclophosphamide, and bleomycin have been shown to trigger nuclear accumulation of the tumor suppressor protein p53 (6, 62).”
InfluentialSelf-citationCellular stress response and apoptosis in cancer therapy
Herr, I., & Debatin, K.-M. (2001) · Blood · doi:10.1182/blood.v98.9.2603 · Cited by 800
Nagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
Apoptosis and cancer: the genesis of a research field
Cotter, T. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2663 · Cited by 758
Oxidative stress and apoptosis: Impact on cancer therapy
Ozben, T. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20874 · Cited by 751
Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., & Green, D. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80054-4 · Cited by 721
Bleomycins: towards better therapeutics
Chen, J., & Stubbe, J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1547 · Cited by 664
Clément, M.-V., Hirpara, J. L., Chawdhury, S.-H., & Pervaiz, S. (1998) · Blood · doi:10.1182/blood.v92.3.996 · Cited by 611
The cellular response to p53: the decision between life and death
Sionov, R. V., & Haupt, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203130 · Cited by 601
Apoptosis: a mechanism of acute and chronic liver injury
Guicciardi, M. E., & Gores, G. J. (2005) · Gut · doi:10.1136/gut.2004.053850 · Cited by 514
Death receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Self-citationHuang, C.-Y., Ju, D.-T., Chang, C.-F., Muralidhar Reddy, P., & Velmurugan, B. K. (2017) · BioMedicine · doi:10.1051/bmdcn/2017070423 · Cited by 481
Apoptosis pathways in cancer and cancer therapy
Debatin, K.-M. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0474-8 · Cited by 476
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Self-citationGenestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., & Revillard, J. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2676 · Cited by 459
Anto, R. J. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.143 · Cited by 429
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
Maier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
Krammer, P. H. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60402-2 · Cited by 394
Self-citationThe Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction
Los, M., Wesselborg, S., & Schulze-Osthoff, K. (1999) · Immunity · doi:10.1016/s1074-7613(00)80062-x · Cited by 391
Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid
Fulda, S., Scaffidi, C., Susin, S. A., Krammer, P. H., Kroemer, G., Peter, M. E., & Debatin, K.-M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.33942 · Cited by 369
Self-citationApoptosis: mechanisms and relevance in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1065-x · Cited by 344
Cell death induced by the Fas/Fas ligand pathway and its role in pathology
Waring, P., & Müllbacher, A. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00837.x · Cited by 322
Wesselborg, S., Engels, I. H., Rossmann, E., Los, M., & Schulze-Osthoff, K. (1999) · Blood · doi:10.1182/blood.v93.9.3053 · Cited by 292
Apoptosis, cancer and cancer therapy
Bold, R. J., Termuhlen, P. M., & McConkey, D. J. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)00015-7 · Cited by 283
Cisplatin Induces Apoptosis in LLC-PK1 Cells via Activation of Mitochondrial Pathways
Park, M. S., De Leon, M., & Devarajan, P. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v134858 · Cited by 279
Strand, S., Hofmann, W. J., Grambihler, A., Hug, H., Volkmann, M., Otto, G., Wesch, H., Mariani, S. M., Hack, V., Stremmel, W., et al. (1998) · Nature Medicine · doi:10.1038/nm0598-588 · Cited by 278
Self-citationEischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., & Kaufmann, S. H. (1997) · Blood · doi:10.1182/blood.v90.3.935 · Cited by 269
Cisplatin-Associated Nephrotoxicity and Pathological Events
Taguchi, T., Nazneen, A., Abid, M. R., & Razzaque, M. S. (2005) · Contributions to Nephrology · doi:10.1159/000086055 · Cited by 256
TAp63α induces apoptosis by activating signaling via death receptors and mitochondria
Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze‐Bergkamen, H., Maria Lena, A., Candi, E., Terrinoni, A., Valeria Catani, M., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600708 · Cited by 255
Self-citationToxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells
Burczynski, M. E. (2000) · Toxicological Sciences · doi:10.1093/toxsci/58.2.399 · Cited by 253
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis
Engels, I. H., Stepczynska, A., Stroh, C., Lauber, K., Berg, C., Schwenzer, R., Wajant, H., Jänicke, R. U., Porter, A. G., Belka, C., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203824 · Cited by 252
Fas Ligand: A Sensor for DNA Damage Critical in Skin Cancer Etiology
Hill, L. L., Ouhtit, A., Loughlin, S. M., Kripke, M. L., Ananthaswamy, H. N., & Owen-Schaub, L. B. (1999) · Science · doi:10.1126/science.285.5429.898 · Cited by 245
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Wang, L., Azad, N., Kongkaneramit, L., Chen, F., Lu, Y., Jiang, B.-H., & Rojanasakul, Y. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3072 · Cited by 151
Pirnia, F., Schneider, E., Betticher, D. C., & Borner, M. M. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401062 · Cited by 151
Stabilization of p53 Is Involved in Quercetin-Induced Cell Cycle Arrest and Apoptosis in HepG2 Cells
TANIGAWA, S., FUJII, M., & HOU, D.-X. (2008) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.70680 · Cited by 135
Munsch, D., Watanabe-Fukunaga, R., Bourdon, J.-C., Nagata, S., May, E., Yonish-Rouach, E., & Reisdorf, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3867 · Cited by 131
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
“Furthermore, there is evidence that CD95 function is required for optimal cell killing by DNA-damaging agents (Friesen et al., 1996; Muller et al., 1997; Embree-Ku et al., 2002), although this may hold only for some cell types and not for others (Newton and Strasser, 2000).”
BackgroundSelf-citationTumor counterattack: Fact or fiction?
Igney, F. H., & Krammer, P. H. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0680-7 · Cited by 98
“, after induction by chemotherapy [23, 26, 66].”
BackgroundSelf-citation(2002) · PubMed · Cited by 89
van Oosten, M., Rebel, H., Friedberg, E. C., van Steeg, H., van der Horst, G. T. J., van Kranen, H. J., Westerman, A., van Zeeland, A. A., Mullenders, L. H. F., & de Gruijl, F. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200226697 · Cited by 82
Hill, L. L., Shreedhar, V. K., Kripke, M. L., & Owen-Schaub, L. B. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1285 · Cited by 75
“Fas and FasL are complementary receptor–ligand proteins that induce apoptosis in many cell types (30).”
BackgroundInfluentialActive transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family
Schilling, T., Schleithoff, E. S., Kairat, A., Melino, G., Stremmel, W., Oren, M., Krammer, P. H., & Müller, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.063 · Cited by 43
Self-citation
Metadata
- Authors
- Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-02-01
- Volume
- 99
- Issue
- 3
- Pages
- 403-413
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2111714805
- Cited by
- 748
- References
- 69
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.